NASDAQ:TCRT Alaunos Therapeutics Q2 2023 Earnings Report $4.99 +0.06 (+1.22%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$5.32 +0.33 (+6.69%) As of 07:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings History Alaunos Therapeutics EPS ResultsActual EPS-$6.00Consensus EPS -$6.00Beat/MissMet ExpectationsOne Year Ago EPSN/AAlaunos Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAlaunos Therapeutics Announcement DetailsQuarterQ2 2023Date8/14/2023TimeQ2 2023 Earnings ReleaseConference Call DateMonday, August 14, 2023Conference Call Time7:00AM ETUpcoming EarningsAlaunos Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Thursday, August 14, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Alaunos Therapeutics Earnings HeadlinesAlaunos Therapeutics Taps Board Member Weis as Next CEOJuly 2, 2025 | marketwatch.comAlaunos Therapeutics, Inc. (TCRT) - Yahoo FinanceJune 26, 2025 | finance.yahoo.com3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. July 14 at 2:00 AM | Timothy Sykes (Ad)Alaunos Therapeutics Raises $850,000 in Private OfferingJune 26, 2025 | tipranks.comAlaunos Therapeutics Announces $2.0 Million Registered Direct Offering - MorningstarJune 24, 2025 | morningstar.comMAlaunos Therapeutics Announces $2.0 Million Registered Direct OfferingJune 23, 2025 | globenewswire.comSee More Alaunos Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alaunos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alaunos Therapeutics and other key companies, straight to your email. Email Address About Alaunos TherapeuticsAlaunos Therapeutics (NASDAQ:TCRT) (NASDAQ: TCRT) is a clinical‐stage biotechnology company focused on developing in vivo cell reprogramming therapies for neurodegenerative diseases and chronic pain. By harnessing proprietary gene delivery platforms, Alaunos aims to convert resident support cells in the central nervous system into functional neurons or inhibitory interneurons, offering potential long-lasting treatments for conditions with high unmet medical need. The company’s lead program targets amyotrophic lateral sclerosis (ALS) through adeno-associated virus (AAV) vectors that deliver neural lineage factors to reprogram astrocytes into motor neurons, with the goal of restoring neuromuscular function. A second preclinical initiative seeks to alleviate neuropathic pain by converting spinal cord glial cells into GABAergic interneurons, potentially providing durable pain relief without the drawbacks of systemic analgesics. Founded in 2017 and headquartered in Cambridge, Massachusetts, Alaunos leverages a multidisciplinary research footprint spanning North America and Europe. The organization maintains strategic collaborations with leading academic institutions and contract research partners to advance its platform technology, optimize vector design and manufacture clinical-grade materials in accordance with regulatory standards. Under the leadership of President and Chief Executive Officer Dr. Ryan Berry, a molecular neuroscientist with extensive experience in gene therapy development, Alaunos has assembled a management team with expertise in translational neuroscience, clinical development and regulatory affairs. The company remains focused on progressing its pipeline through IND-enabling studies and initial human trials, with the aim of delivering transformative therapies to patients suffering from ALS and neuropathic pain.Written by Jeffrey Neal JohnsonView Alaunos Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s Next Upcoming Earnings America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025)ASML (7/16/2025)Bank of America (7/16/2025)The Goldman Sachs Group (7/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
